The US FDA needs to get a better systematic handle on how well it is implementing the 20-year-old "least-burdensome" provisions with respect to requests for additional information during pre-market reviews, according to the US Government Accountability Office.
GAO says in a report posted Jan. 16 that FDA should establish formal performance metrics to evaluate how well...